Category: Obesity Treatment

AT A GLANCE STAT reports The Outsourcing Facilities Association, has sued the FDA for a ‘reckless and arbitrary’ decision to remove tirzetapide from the shortages list. Eli Lilly is sending hundreds of cease-and-desist letters to telehealth companies, compounding pharmacies and medical spas, from Bloomberg. Christina Farr at Second Opinion asks Could we have hit “peak obesity” The Congressional Budget Office reports on the estimated budgetary effects of an illustrative policy to

AT A GLANCE Terns Pharmaceuticals released data that 67% of patients taking the highest dose of TERN-601 lost at least 5% of their body weight at 28 days. STAT on Novo Nordisk reported that its new obesity pill that targets the amylin hormone led to substantial weight loss in an early study. Trust for America’s Health on obesity rates for U.S. adults were at or higher than 35

AT A GLANCE Eli Lilly reports tirzetapide ‘…reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight.’ Modern Healthcare reports that ‘…employers budgeting for a 7.8% increase in healthcare costs in 2025. Lose the weight, or lose state-funded healthcare, says The Telegraph newspaper from the UK. JAMA Network Open publishes a review of World Health Organization data, of 107 suicidal

AT A GLANCE The Guardian newspaper reports ‘…Much of the NHS does not take obesity seriously enough.’ Reuters on only ‘…one in four U.S. patients prescribed Novo Nordisk’s Wegovy or Ozempic for weight loss were still taking the popular medications two years later.’ Vivani Medical plans to launch an investigational six-month program for its GLP-1 implant NPM-115. Rani Therapeutics, announces commercialization of RT-114, an oral

AT A GLANCE Nature journal reports ‘…People with HIV are the latest group to benefit from the new generation of anti-obesity drugs.’ STAT suggests FDA approval of Wegovy for heart benefits ‘…could provide a backdoor way to expand access to the drug for people on Medicare.’ Peter Loftus at The Wall Street Journal reveals those ‘…seeking a popular new weight-loss drug will have a new home-delivery option from

AT A GLANCE Novo Nordisk’s FLOW trial of Ozempic demonstrates a ‘…24% reduction in the risk of kidney disease-related events…’ STAT reports on Novo Nordisk’s phase 1 trial of experimental oral medicine amycretin, with an average of 13.1% weight loss after 12 weeks. Reuters informs on Novo Nordisk market cap of $556 billion and had surpassed that of Tesla. The FDA approved ‘…a new indication for use